In Trading, Results Matter.
Our Top 10 exits in last 5 trading days.

Aimmune Therapeutics, Inc.. Trade Record

NASDAQ:AIMT Aimmune Therapeutics, Inc. stock gains 17.09% Exit Dec 4, 2017 a Trade Record by priceseries

Trade Chart
Trade Chart AIMT Nov 8, 2017, priceSeries
About Aimmune Therapeutics, Inc.

Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies in the United States and Europe. Its lead Characterized Oral Desensitization ImmunoTherapy product candidate is AR101, an investigational biologic for the treatment of patients with peanut allergy. Aimmune Therapeutics, Inc. has strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics. The company was formerly known as Allergen Research Corporation and changed its name to Aimmune Therapeutics, Inc. in May 2015. The company was founded in 2011 and is headquartered in Brisbane, California.

Trade Information
Trade Type
LONG
ReliabilityScore™
99.60
Entry Date
Nov 8, 2017
Entry Price
30.94
Sell Date
Dec 4, 2017
Sell Price
36.23
Net Gain
17.09%
Hold Time
17 Trading Days